Advertisement
Letter to the editor|Articles in Press

Neurodevelopmental disorders after prenatal exposure to topiramate: A lost decade idly watching from the sidelines

      Knight and colleagues must be commended for their cross-sectional study from the UK Epilepsy and Pregnancy Register evidencing that children exposed to topiramate in utero had poorer levels of adaptive behaviour with a dose response effect [
      • Knight R.
      • et al.
      Adaptive behaviour in children exposed to topiramate in the womb: an observational cohort study.
      ].

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Seizure - European Journal of Epilepsy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Knight R.
        • et al.
        Adaptive behaviour in children exposed to topiramate in the womb: an observational cohort study.
        Seizure. 2023; 105: 56-64
        • Rihtman T.
        • et al.
        Preliminary findings of the developmental effects of in utero exposure to topiramate.
        Reprod Toxicol. 2012; 34: 308-311
        • Bjørk M.H.
        • et al.
        Association of prenatal exposure to antiseizure medication with risk of autism and intellectual disability.
        JAMA Neurol. 2022; 79 ([published correction appears in JAMA Neurol. 2022 Jul 1;79(7):727]): 672-681
        • Bech L.F.
        • et al.
        In utero exposure to antiepileptic drugs is associated with learning disabilities among offspring.
        J Neurol Neurosurg Psychiatry. 2018; 89: 1324-1331
        • Blotière P.O.
        • et al.
        Risk of early neurodevelopmental outcomes associated with prenatal exposure to the antiepileptic drugs most commonly used during pregnancy: a French nationwide population- based cohort study.
        BMJ Open. 2020; 10e034829
        • Hernandez-Diaz
        • et al.
        Topiramate during pregnancy and the risk of neurodevelopmental disorders in children.
        in: Proceedings of the 38th international conference on pharmacoepidemiology and therapeutic risk management, Copenhagen, Denmark31. 2022: 47 (26–28 August 2022Harmacoepidemiology and Drug Safety#)
        • Bjørk M.H.
        • et al.
        Association of folic acid supplementation during pregnancy with the risk of autistic traits in children exposed to antiepileptic drugs in utero.
        JAMA Neurol. 2018; 75: 160-168
        • Collective
        [Topiramate and risks in children exposed during pregnancy: modification of the conditions of prescription and delivery to the women concerned].
        Agence Natl Sécur Méd Prod Santé. 2022; (6 Octoberupdated 2 November 2022. Available at) (Accessed 4 March 2023)
        • Clincalc.com.
        Topiramate.
        Drug Usage Statistics, United States2020 (2013 –Available at) (Accessed 4 March 2023)
        • Wise J.
        Pregnant women should be included in clinical trials to improve outcomes, says commission.
        BMJ. 2022; 377: o1193
        • Sarayani A.
        • et al.
        Prenatal exposure to teratogenic medications in the era of risk evaluation and mitigation strategies.
        Am J Obstet Gynecol. 2022; 227: 263.e1-263.e38
        • Stancil S.L.
        • Miller M.
        • Briggs H.
        • Lynch D.
        • Goggin K.
        • Kearns G.
        Contraceptive provision to adolescent females prescribed teratogenic medications.
        Pediatrics. 2016; 137https://doi.org/10.1542/peds.2015-1454